NVIDIA tie-up targets up to 75% faster drug-modeling workflows

Pharmacokinetics/pharmacodynamics (PK/PD) describe how a drug moves through the body (how quickly it’s absorbed, distributed, and removed) and how the drug produces its effects (how strong and how long the effect lasts). Think of PK as how fast and how much coffee gets into your system and PD as how awake it makes you and for how long. For investors, PK/PD data signal whether a medicine can be dosed safely and effectively, shape regulatory and commercial prospects, and reduce the risk of late-stage failure.

Model-informed drug development uses computer-based math models and simulations of how a drug behaves in the body and how patients respond to guide decisions across research and clinical trials. Like a flight simulator for drug programs, it helps teams test scenarios, pick better doses, design smarter trials and reduce surprises, which can lower costs, shorten timelines and de-risk programs—information investors use to judge a drug’s chances and capital efficiency.

Using graphics processing…